본문 바로가기 주메뉴 바로가기

제품소개

제품상세페이지

Accegen

[Accegen] SUIT-2

Cat-No. ABC-TC1175

upload_image



미국 Accegen은 생명과학 연구와 의약품 개발을 지원하기 위해 다양한 세포주와 생물학적 제품을 제공하는 바이오 제품 제조 기업입니다.








제품 설명


SUIT-2




제품 번호


ABC-TC1175




제품 특징


Product Code

Suit-2; SUIT 2; SUIT2; Suit2; SUIzo Tumor-2

Species

Human

Cat.No

ABC-TC1175

Product CategoryTumor Cell Lines
Size/Quantity

1 vial

Cell Type

Epithelial-like

Shipping Info

Dry Ice

Growth Conditions

37 ℃, 5% CO2

Biosafety Level

1

Storage

Liquid Nitrogen

Product Type

Human Pancreas Cancer Cell Lines



Description


SUIT-2 is a human pancreatic cancer cell line derived from a liver metastasis of moderately differentiated tubular adenocarcinoma in a Japanese male patient. The cells exhibit an epithelial-like morphology with two distinct subpopulations under phase-contrast microscopy: one spindle-shaped and elongated, the other polygonal and epithelial. SUIT-2 cells express several pancreatic ductal markers including carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CSPG2/versican, and Mac25/angiomodulin. Electron microscopy confirms features of pancreatic ductal epithelium. Karyotype analysis shows aneuploidy, consistent with malignant transformation. SUIT-2 cells are tumorigenic and metastatic, capable of forming tumors and spreading to regional lymph nodes in nude mouse xenografts.




Citation


When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).

Chen, W.C., To, M.D., Westcott, P.M., Delrosario, R., Kim, I.J., Philips, M., Tran, Q., Bollam, S.R., Goodarzi, H., Bayani, N. and Mirzoeva, O., 2021. Targeting KRAS4A splicing through the RBM39/DCAF15 pathway inhibits cancer stem cells. Nature communications, 12(1), pp.1-14.


Application


      • SUIT-2 is a useful tool to investigate the biological activity of pancreatic ductal adenocarcinoma, identify novel targets or markers for diagnosis, prognosis, and therapy, and contribute to understanding of the interactions between cancer and the host. For example, SUIT-2 can be used to demonstrate how growth factors regulate cell proliferation of tumor cells and the impact of motility-related factors on migration and metastasis.



Frequently Asked Questions


  • What is the doubling time of JIMT-1 cell line?

    JIMT-1 cell line doubling time is 30-40h, and it is recommended to change medium every 2-3 days.

  • What is the property of JIMT-1 cell?

    JIMT-1 cells overexpress HER-2 mRNA and are insensitive to drugs that inhibit HER-2 (such as trastuzumab). JIMT-1 cells have an amplified HER-2 oncogene, which showed no identifiable mutations in its coding sequence.

    The cell line lacks expression of hormone receptors (estrogen receptors and progesterone receptors) and is phenotypically of epithelial progenitor cell origin.

  • What is the suggested cell culture concentration (cells/ml) of JIMT-1 cell line?

    The recommended cell density for JIMT-1 cells before passage is 1-2 × 10^5 cells/mL. We recommend to use a T-25 setup at a dilution of 1:5-1:10 (our cell count is approximately 1-2M/vial).




Accegen의 모든 제품들을 만나 보세요!

 

PRODUCTS



Accegen - Official Distributor in South Korea "Morebio" 한국 공식 대리점 "모아바이오"